33 completed, 10 unknown, 5 withdrawn, 4 terminated. 52 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 52 | Completed 33, Unknown 10, Withdrawn 5, Terminated 4 |
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide - Exudative Age Related Macular Degeneration | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-03-30 | 2024-03-22 | |
| Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Intravitreal ranibizumab, Intravitreal bevacizumab - Diabetic Macular Edema, Macular Ischemia | Phase 4 | Terminated | Cairo University | 5 | 2021-11-26 | 2023-02-16 |
| Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML [Lucentis] - Wet Macular Degeneration | Phase 4 | Withdrawn | Faculty Hospital Kralovske Vinohrady | 2021-01-04 | 2022-08-10 | |
| Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema Ranibizumab, Sham injection, Pars plana vitrectomy - Proliferative Diabetic Retinopathy, Diabetic Macular Edema | Phase 4 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 142 | 2020-09-01 | 2020-07-09 |
| Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Ranibizumab, laser photocoagulation - Retinal Vein Occlusion, Treatment | Phase 4 | Unknown | Sun Yat-sen University | 100 | 2019-10-01 | 2019-08-20 |
| Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification Bevacizumab, Ranibizumab, Aflibercept - Diabetic Macular Edema, Cataract | Phase 4 | Completed | Bay Area Retina Associates | 16 | 2018-11-15 | 2025-09-12 |
| Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion Aflibercept Injection [Eylea], Ranibizumab Injection [Lucentis] - Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | St. Erik Eye Hospital | 110 | 2018-10-18 | 2024-10-28 |
| Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME Intravitreal Ranibizumab, Micropulse Laser, Intravitreal Ranibizumab as needed - Diabetic Macular Edema | Phase 4 | Completed | Beijing Hospital | 72 | 2018-10-01 | 2022-12-28 |
| Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Lucentis - Diabetic Macular Edema | Phase 4 | Completed | Vitreo-Retinal Associates, Michigan | 10 | 2017-04-19 | 2022-10-24 |
| Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy ranibizumab - Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Unknown | Pusan National University Hospital | 28 | 2016-11-22 | 2019-10-10 |
| Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose PDT, Ranibizumab, ranibizumab PRN - Age-related Macular Degeneration | Phase 4 | Unknown | Seoul National University Hospital | 40 | 2016-09-01 | 2016-08-12 |
| 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. Ranibizumab, Aflibercept - Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2016-09-01 | 2017-04-28 | |
| Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration Ranibizumab - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Johannes Gutenberg University Mainz | 71 | 2016-08-05 | 2017-12-02 |
| Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy Lucentis - Nonproliferative Diabetic Retinopathy | Phase 4 | Completed | Wonkwang University Hospital | 25 | 2016-08-01 | 2020-05-22 |
| Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Lucentis - Wet Macular Degeneration | Phase 4 | Completed | Seoul National University Hospital | 20 | 2016-03-03 | 2018-04-19 |
| Head to Head Study of Anti-VEGF Treatment. ranibizumab, Conbercept - Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 12 | 2016-01-13 | 2017-11-30 |
| Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Ozurdex, Lucentis - Diabetic Macular Edema | Phase 4 | Terminated | North Toronto Eye Care Laser and Eye Specialists | 5 | 2015-11-01 | 2018-08-20 |
| Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Ranibizumab, Aflibercept - Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2015-10-01 | 2016-10-27 | |
| Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Ranibizumab, Laser - Central Retinal Vein Occlusion With Macular Edema | Phase 4 | Unknown | PD. Dr. med. Armin Wolf | 60 | 2015-08-01 | 2015-08-13 |
| Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Ranibizumab 0.5 mg, Aflibercept 2 mg - Wet Age-Related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 41 | 2015-04-08 | 2019-05-07 |
Showing 20 of 52. Sign in to see all of them.
Macular Degeneration (17) · Macular Edema (6) · Retinal Vein Occlusion (6) · Diabetic Retinopathy (5) · Choroidal Neovascularization (4) · Polypoidal Choroidal Vasculopathy (3) · Diabetes Complications (2) · Diabetes Mellitus (2) · Retinal Detachment (2) · Retinal Diseases (2) · Wet Macular Degeneration (2) · Cataract (1) · Cerebrovascular Disorders (1) · Coronary Artery Disease (1) · Edema (1)
Novartis Pharmaceuticals (9) · Medical University of Vienna (2) · Moorfields Eye Hospital NHS Foundation Trust (2) · Seoul National University Hospital (2) · Anders Kvanta (1) · Bay Area Retina Associates (1) · Beijing Hospital (1) · Cairo University (1) · Centre Hospitalier Intercommunal Creteil (1) · Charles C Wykoff, PhD, MD (1) · David M. Brown, M.D. (1) · Faculty Hospital Kralovske Vinohrady (1) · Federal University of São Paulo (1) · GWT-TUD GmbH (1) · Genentech, Inc. (1)
United States (11) · Germany (7) · China (5) · South Korea (4) · Australia (3) · United Kingdom (3) · Austria (2) · Canada (2) · Hong Kong (2) · Japan (2) · Singapore (2) · Sweden (2) · Taiwan (2) · Thailand (2) · Brazil (1)
Ahmed A Abdel-Kader, MD, PhD (1) · Ahmed A Mohalhal, MD, PhD (1) · Alexander Kharlamov, M.D., Ph.D. (1) · Anders Kvanta, MD PhD (1) · Andreas Moan (1) · Armin Wolf, PD Dr. (1) · Ayman G Elnahry, MD, PhD (1) · Caesar Luo, MD (1) · Carol L Shields, MD (1) · Charles C Wykoff, PhD, MD (1) · Chenjin Jin, Ph.D (1) · Christian Pruente, MD (1) · Christina Korb, MD (1) · David M Brown, M.D. (1)
PMID 19584650, PMID 21051706, PMID 21278146, PMID 21901296, PMID 22426346, PMID 23490325, PMID 23745581, PMID 25758601, PMID 25957377, PMID 26888975, PMID 27009515, PMID 27409478, PMID 28084038, PMID 28318636, PMID 28498374, PMID 28983556, PMID 29080915, PMID 30621653, PMID 30676617, PMID 31139483, PMID 31687203, PMID 32374423, PMID 32411431, PMID 32427087, PMID 32644148, PMID 32672800, PMID 32727496, PMID 32844399, PMID 33206392, PMID 33784213, PMID 34124270, PMID 34189816, PMID 35217515, PMID 35976232, PMID 36056443, PMID 36646240, PMID 37260074, PMID 38308746, PMID 40504425
2009 (2), 2014 (1)